Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

Wyeth Pharmaceuticals (December 2008)

By the end of 2008 Santaris Pharma entered into an agreement with Wyeth Pharmaceuticals, covering 10 LNA-based drug candidates targeting various diseases selected by Wyeth. Under the terms of the collaboration Santaris Pharma will design and generate the drug compounds and Wyeth will be responsible for all preclinical- and clinical development as well as the commercialization on a worldwide basis.

GlaxoSmithKline Collaboration (December 2007)

Under the terms of the collaboration with GlaxoSmithKline (GSK) on new drugs for the treatment of viral diseases, Santaris Pharma is responsible for the discovery and development of RNA inhibiting drug candidates through to completion of Phase IIa ("Clinical Proof of Concept") for four viral targets, at which point GlaxoSmithKline will have an exclusive option to license each compound for further development and commercialisation on a worldwide basis. Presently GSK has selected one viral disease target and Santaris Pharma has identified several strong drug candidates against the target.

Enzon Collaboration (August 2006)

Under the terms of the collaboration with Enzon Pharmaceuticals, Santaris Pharma will design and generate a total of eight drug candidates and Enzon will fund and manage the preclinical- and clinical development of the drug candidates and file for regulatory approvals outside Europe. Santaris Pharma has maintained all commercial rights for the eight drug candidates in Europe.

Enzon is expected to disclose final results from the clinical development of EZN/SPC2968, a HIF-1alpha inhibitor, which is currently being evaluated in two separate Phase I/II clinical trials in patients with advanced solid tumors, in the 2nd half of 2009.

Enzon has initiated a Phase I study in various solid tumors for EZN/SPC3042, the Survivin inhibitor, in the 1st quarter of 2009.


'/>"/>
SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... to Divest Non-Strategic Assets and ... Financial Performance, NATICK, Mass., Aug. 16 Boston Scientific,Corporation ... the sale,of its Cardiac Surgery and Vascular Surgery businesses as ... and divest those,considered non- strategic, and to strengthen its operating ...
... FRANCISCO, Calif., Aug. 16 Anesiva,Inc. (Nasdaq: ... the,Zingo(TM) development program before the markets open tomorrow. ... at 8:30 a.m. Eastern Time,tomorrow to discuss the ... live audio webcast by dialing,800-340-6289 (international dial: 706-634-1538) ...
... is First Commercial Product for Anesiva - ... for Today at 8:30 a.m. ET -, SOUTH ... ANSV ) announced today that the U.S. Food and ... injection system, which provides rapid,topical, local analgesia to reduce ...
Cached Biology Technology:Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses 2Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses 3Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 3Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 4Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 5
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
(Date:7/10/2014)... 8, 2014 Fingerprint Cards, ... design win (DW). An Asian OEM has selected FPC1021 for ... start in August 2014.   FPC is proud ... has a planned date for start of mass production in ... of SEK 5M, for delivery in the first half of ...
(Date:7/10/2014)... main organization of the International Science and Business Belt ... of researchers, led by professor Won Do Heo, have ... that can remotely control specific receptors by light. They ... succeeded with neuronal differentiation inducement. , The most significant ... light to activate neuronal functions without the need of ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2New optogenetic tool for controlling neuronal signalling by blue light 2
... Climate change, a recent hot topic when studying the ... another important factor to this global phenomenon is still ... to see the possible effects of climate change on ... waters, and groundwater are responding to climate change. ...
... When the space shuttle Endeavour touched down at ... Medical Branch at Galveston microbiology and immunology department chairman ... to a reunion with some of its passengers. ... were Streptococcus pneumoniae bacteria, members of a species commonly ...
... recently physicians have had to rely on time-consuming and ... diseases such as multiple sclerosis, Alzheimer,s and schizophrenia. ... Journal of Neural Engineering suggests that we could soon ... diseases by analysing the tiny magnetic fields produced by ...
Cached Biology News:Climate change goes underground 2Climate change goes underground 3Shuttle brings space-grown strep bacteria back for study 2Shuttle brings space-grown strep bacteria back for study 360 second test could help early diagnosis of common brain diseases 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
Biology Products: